Skip to content

Pituitary Function and Spontaneous Intracranial Hypotension

Spontaneous Spinal Cerebrospinal Fluid Leaks and Intracranial Hypotension

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02603549
Enrollment
100
Registered
2015-11-13
Start date
2015-07-31
Completion date
2020-12-31
Last updated
2019-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperprolactinemia, Spontaneous Intracranial Hypotension

Brief summary

Previous research has identified spontaneous cerebral spinal fluid leakage as a cause for spontaneous intracranial hypotension, leading to positional headache patterns. Typical magnetic resonance imaging findings include subdural fluid collections, enhancement of pachymenginges, engorgement of venous structures, pituitary hyperemia, and sagging of the brain (SEEPS). Because pituitary hyperemia has been documented in cases of spontaneous cerebral spinal fluid leakage and is known to mimic a pituitary tumor or hyperplasia, the investigators would like to like to assess the clinical manifestations and neuroimaging abnormalities of SIH patients with regard to the pituitary gland. Specifically, the investigators are looking to analyze the compression of the pituitary stalk and conduct a systemic evaluation of pituitary function in SIH patients.

Interventions

OTHERPituitary panel will be drawn pre-op and post-op for all patients.

Sponsors

Cedars-Sinai Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female patients * Age 18 years and older * Diagnosis of SIH: * LP * Brain MRI (SEEPS)

Exclusion criteria

* Pregnant and post-partum females * Nursing mothers * Patients with potential hyperprolactinemia due to: * Hypothyroidism, * Chronic renal disorder * Liver disease (including cirrhosis) * Primary or secondary amenorrhea * Polycystic Ovary Syndrome * Seizure disorder * Illicit drug use

Design outcomes

Primary

MeasureTime frame
Comparing the levels of prolactin pre and post treatment90 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026